denotes an abstract that is clinically relevant.
denotes that this is a ticketed session.
Description:
This session will focus on advances in of myelodysplastic syndromes, including proposed changes in the classification of these disorders, precursor or related proliferations and the outlook for new therapies.
Dr. Daniel Arber will present proposed changes to the 2008 World Health Organization (WHO) classification of myelodysplastic syndromes, including the incorporation of genetic changes, the refining of existing disease categories and general nomenclature changes. He will present the process used by the WHO for making classification changes as well as the rationale for the changes that are proposed for the upcoming revision to be published in 2016.
Dr. Luca Malcovati will examine the borderland of the current definition of myelodysplastic syndromes. He will discuss biological clues and clinical approach to conditions not fulfilling the criteria for diagnosis of myelodysplastic syndrome, currently grouped under the designation of idiopathic cytopenia of undetermined significance, and focus on clinical and biological implications of hematopoietic clones arising upon aging or in acquired cytopenias.
Dr. Amy DeZern will present the current state of therapeutics in myelodysplastic syndromes (MDS). She will describe the current challenges in MDS as they pertain to new drug availability. She will review the status of novel agents that have been studied in the disease and the outlook for future treatments in this population.